Stiripentol

An anticonvulsant, FDA-approved with clobazam for seizures of Dravet syndrome in patients 6 months and older.

psilodex.org/m/stiripentol · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: 4.5–13 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado Condition rules (3)

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Stiripentol”, v2026.10.05. psilodex.org/m/stiripentol

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Seizures of Dravet syndrome (taken with clobazam, age 6 months and older)

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin; it blocks an enzyme that clears psilocybin, so higher levels are possible. Stopping it suddenly after regular use can cause seizures.

Detail There are no psilocybin data. Its label states it inhibits (blocks) the liver enzymes CYP3A4 and CYP2C19. CYP3A4 metabolized psilocin (psilocybin's active form) in lab studies, so psilocin levels may rise (untested). Its label reports marked sleepiness. Also, it carries the antiepileptic class warning about suicidality, and stopping it abruptly carries seizure risk. Sources [1][2]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Half-life: 4.5–13 h (FDA label, checked 2026-10-04) Increases with dose.

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

3 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Sources [1]
Psychiatric reactions: The label or source warns of psychiatric effects such as psychosis, mania, hallucinations, suicidal thoughts or severe mood or behavior changes. Psilocybin can also bring up strong emotions, so these warnings are relevant to screening. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Seizure disorder (usual indication)
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees

05 Sources

DIACOMIT (stiripentol) capsule and powder for suspension · FDA label (DailyMed) — revised 2026-04 | Sedating or CNS depressant: 5.1 Somnolence "DIACOMIT can cause somnolence." | Withdrawal or rebound if stopped abruptly: 5.4 Withdrawal of Antiepileptic Drugs "to minimize the risk of increased seizure frequency and status epilepticus" | Psychiatric reactions: 5.6 Suicidal Behavior and Ideation "AEDs, including DIACOMIT, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication." | 7.1 Effect of DIACOMIT on Other Drugs "Co-administration of DIACOMIT (which inhibits CYP 3A4 and 2C19) with clobazam results in increased plasma concentrations of clobazam" | 12.3 Pharmacokinetics "The elimination half-life of stiripentol ranges from 4.5 to 13 hours, increasing with doses of 500 mg, 1000 mg and 2000 mg."
Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689. — Lab studies: MAO-A, CYP2D6 and CYP3A4 metabolized psilocin; glucuronidation and conversion to 4-HIAA are the main routes.

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →